tiprankstipranks

Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions

Story Highlights

Medacta Group SA ( (CH:MOVE) ) has issued an announcement.

Medacta Group SA reported a strong financial performance for 2024, with revenue increasing by 16.2% in constant currency to Euro 590.6 million and an adjusted EBITDA margin of 28.0%. The company attributes its success to innovative product launches, such as the GMK SpheriKA knee implant and the NextAR Rod Optimizer, which enhance surgical planning and patient outcomes. Medacta’s expansion efforts, including facility enlargements and workforce growth, aim to meet rising demand and support future growth. The company anticipates continued revenue growth in 2025, driven by its commitment to cutting-edge technologies and personalized medical solutions.

More about Medacta Group SA

Medacta Group SA operates in the medical technology industry, focusing on innovative orthopedic solutions. The company specializes in minimally invasive techniques and personalized solutions for joint replacement surgeries, including hip, knee, shoulder, and spine, with a strong emphasis on surgeon education and patient satisfaction.

YTD Price Performance: 22.64%

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.87B

For detailed information about MOVE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App